what are the risks of glp-1 for weight loss Medications Infographic What Are the Side Effects

Nen nhradou pestr stravy

Wegovy contains the same active ingredient as Ozempic but is specifically FDA-approved for chronic weight management in adults with a BMI of 30 or higher or a BMI of 27 or higher with at least one weight-related condition

Est disponible en dosis de 10 y 20g

Patients with favorable GLP1R or GIPR predispositions may achieve clinical goals at lower doses and costs, while those with FTO or MC4R variants may require higher doses or dual-agent compoundschanging the true cost-per-outcome calculation significantly

Early phase trials suggest retatrutide may produce weight loss exceeding tirzepatide, though long-term safety and tolerability data remain limited